Fanhdi

Fanhdi is a human coagulation factor VIII used for intravenous administration. It aids in blood clotting and is essential for managing certain bleeding disorders. This product is manufactured by Instituto Grifols, S.A. in the EU.

Fanhdi is primarily used to manage bleeding episodes in individuals with hemophilia A, a condition characterized by a deficiency in factor VIII. It helps to replace the missing clotting factor, thereby promoting normal blood clotting. This medication is also used to prevent bleeding during surgical procedures in patients with hemophilia A.

Common effects of Fanhdi may include mild reactions at the injection site, such as redness or swelling. Some individuals might experience flu-like symptoms, including fever or chills. Severe allergic reactions are rare but possible and require immediate medical attention.

Fanhdi should be handled with care and stored as per the manufacturer's instructions to maintain its efficacy. It is crucial to use this medication under the supervision of a healthcare professional. Patients should inform their healthcare provider about any known allergies or medical conditions before administration.

Fanhdi may interact with certain medications, including those that affect blood clotting. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and other substances that affect blood clotting should be used with caution.